UAB Hematology Review 2021

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

UAB Hematology Review 2021

Videos
Event

Playback speed

10 seconds

Interferon for PV: Types, MOA, Effects in MPN, Pegylation of IFN, PEG vs. HU for High-Risk Disease, IFN Alfa-2 vs. HU, PEG-IFN Alfa-2b

By UAB Hematology Review 2021 FEATURING Pankit Vachhani

360 views

March 18, 2021

Comments 0

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Videos

Sickle Cell Disease in Clinical Practice: Pathophysiology, Mortality…

UAB Hematology Review 2021

J. Kanter

54 views

New Therapies for Sickle Cell Disease in 2021: Crizanlizumab vs. Pla…

UAB Hematology Review 2021

J. Kanter

293 views

CLL Management in Times of COVID-19: Frontline Acalabrutinib or Ven …

UAB Hematology Review 2021

M. Narkhede

108 views

Advanced Stage cHL: Considering Frontline, Secondary, and Salvage Tr…

UAB Hematology Review 2021

G. Goyal

37 views

Hematopathology Pearls for Clinicians: Danger of “Preliminary Diagno…

UAB Hematology Review 2021

D. Morlote

146 views

2021 Updates on the Use of DOACs: Which GI/GU Patients Are Suitable …

UAB Hematology Review 2021

J. May

28 views

Hematologic Manifestations of COVID-19: Thrombosis Mechanisms and Ri…

UAB Hematology Review 2021

R. Gangaraju

3.6K views

2021 Updates on 2L CML and Beyond: TKIs (Imatinib, Dasatinib/Nilotin…

UAB Hematology Review 2021

O. Jamy

208 views

Interferon for PV: Types, MOA, Effects in MPN, Pegylation of IFN, PE…

UAB Hematology Review 2021

P. Vachhani

360 views

2021 UAB Updates on Relapsed DLBCL: Salvage Chemo+ASCT, Len+Rituxima…

UAB Hematology Review 2021

A. Mehta

217 views

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triple…

UAB Hematology Review 2021

K. Godby

313 views

Incorporating MoAbs in Frontline Treatment of MM: Assessing the Data…

UAB Hematology Review 2021

S. Giri

216 views

Frontline Daratumumab in MM: D-VTd vs. VTd, D-RVd vs. RVd in Transpl…

UAB Hematology Review 2021

S. Bal

97 views

Clinical Pearls: 2021 Review of Recently Approved Agents in Hematolo…

UAB Hematology Review 2021

S. Worth

65 views

UAB 2021 Updates on Frontline MDS: Can We Achieve AUC Decitabine at …

UAB Hematology Review 2021

K. Bachiashvili

69 views